High Protein Diet and Atherosclerosis
University of Missouri-Columbia · NCT05235464
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 45–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 24
- US sites recruiting
- 1
- Study start
- March 13, 2023
- Record last updated
- May 11, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas "lean" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.
Being studied: Standard meal; High animal protein meal; High plant protein meal; High plant protein meal with additional leucine
Conditions: Atherosclerosis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- >=45 and \<=75 years of age
- body mass index >=25.0 and \<40.0 kg/m2
Exclusion Criteria
- \<45 and >75 years of age
- body mass index \<25.0 or >39.9 kg/m2
- plasma triglyceride \<125 mg/dl
- history of or current significant organ system dysfunction
- allergies or intolerances to meal ingredients
- use of medications or dietary supplements that could confound the study outcomes
- engaged in regular structured exercise >150 min per week
- alcohol use disorder
- premenopausal women
- persons who smoke
- prisoners
- inability to grant voluntary informed consent
Recruiting US locations
University of Missouri School of Medicine
Columbia, MO 65212
Site contact: Vasavi Shabrish · v.shabrish@missouri.edu
Study contacts (from the official record)
- Bettina Mittendorfer, PhD · 6186103465 · b.mittendorfer@missouri.edu
Similar studies in Missouri
All heart & blood pressure studies in Missouri →- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Kansas City, MO + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersEarly Phase 1
PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Volunteer - Dosimetry Study)
Washington University School of Medicine
- Location
- St Louis, MO
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
Liver Adiposity Effects on Pediatric Statin
Children's Mercy Hospital Kansas City
- Location
- Kansas City, MO
- Eligibility basics
- Ages 8–21
- RecruitingHealthy volunteersPhase 1
PET Detection of CCR2 in Human Atherosclerosis
Washington University School of Medicine
- Location
- St Louis, MO
- Eligibility basics
- Ages 18–89